Investigation Into Edgewise Therapeutics
Pomerantz LLP has initiated an investigation on behalf of investors in Edgewise Therapeutics, Inc. (NASDAQ: EWTX). The firm is examining allegations regarding potential securities fraud or unlawful business practices involving the company and its officers or directors.
Details of the Clinical Trial Findings
Recently, Edgewise released results from clinical trials focused on its leading asset, sevasemten, aimed at treating Becker and Duchenne muscular dystrophies. While the results were labeled as "positive" by the company, they mentioned that the U.S. FDA found the data insufficient for an expedited approval. This feedback was received during a recent Type C meeting.
Impact on Stock Price
Following this announcement, Edgewise's share price experienced a notable decline, dropping by $1.27, which equated to an 8.86% fall, closing at $14.33. Investors are advised to monitor the situation closely as further developments unfold.
About Pomerantz LLP
Pomerantz LLP stands out as a leading firm with a remarkable track record in corporate, securities, and antitrust litigations. Since its inception over 80 years ago by Abraham L. Pomerantz, the firm has championed the rights of investors facing securities fraud and corporate misconduct, achieving significant financial recoveries for class members.
Firm's Commitment to Protect Investors
Continuing in the legacy of its founder, Pomerantz LLP is dedicated to fighting for the rights of those adversely affected by fraudulent practices within the securities sector. Their expertise and commitment to justice positions them as a formidable ally for investors seeking redress.
Contact Information
If you are a shareholder of Edgewise Therapeutics and wish to discuss your rights, please reach out to Danielle Peyton, who is leading the investigation. You can contact her at 646-581-9980, ext. 7980, for further assistance.
Frequently Asked Questions
What is the investigation about?
Pomerantz LLP is investigating possible securities fraud or unlawful business practices by Edgewise Therapeutics and its management.
What caused the drop in Edgewise's stock price?
The stock price fell after the company reported clinical trial data that the FDA deemed insufficient for expedited approval.
Who can participate in the investigation?
Investors and shareholders of Edgewise Therapeutics are invited to join the investigation.
How can I contact the law firm?
You can reach Danielle Peyton at Pomerantz LLP at 646-581-9980, ext. 7980 for any inquiries related to the investigation.
What is the history of Pomerantz LLP?
Pomerantz LLP has been a pioneer in class action laws focusing on securities fraud for over 80 years, recovering millions for its clients.